{"name":"Saniona","slug":"saniona","ticker":"","exchange":"","domain":"","description":"Saniona is a clinical-stage biopharmaceutical company focused on the discovery and development of novel treatments for rare diseases with significant unmet medical needs. The company's lead product, Tesomet, is currently marketed for the treatment of obesity, while it continues to advance its pipeline of innovative therapies.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Tesomet","genericName":"Tesomet","slug":"tesomet","indication":"Other","status":"discontinued"},{"name":"Tesomet \"High dose\" in fasted condition","genericName":"Tesomet \"High dose\" in fasted condition","slug":"tesomet-high-dose-in-fasted-condition","indication":"Other","status":"marketed"},{"name":"Tesomet \"High dose\" in fed condition","genericName":"Tesomet \"High dose\" in fed condition","slug":"tesomet-high-dose-in-fed-condition","indication":"Chronic weight management in obese or overweight adults","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Tesomet \"Low dose\" in fasted condition","genericName":"Tesomet \"Low dose\" in fasted condition","slug":"tesomet-low-dose-in-fasted-condition","indication":"Obesity or overweight with comorbidities (marketed in Europe)","status":"marketed"}]}],"pipeline":[{"name":"Tesomet","genericName":"Tesomet","slug":"tesomet","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tesomet \"High dose\" in fasted condition","genericName":"Tesomet \"High dose\" in fasted condition","slug":"tesomet-high-dose-in-fasted-condition","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tesomet \"High dose\" in fed condition","genericName":"Tesomet \"High dose\" in fed condition","slug":"tesomet-high-dose-in-fed-condition","phase":"marketed","mechanism":"Tesomet is a combination of tesofensine (a monoamine reuptake inhibitor) and metformin that promotes weight loss by increasing satiety and energy expenditure while improving metabolic control.","indications":["Chronic weight management in obese or overweight adults"],"catalyst":""},{"name":"Tesomet \"Low dose\" in fasted condition","genericName":"Tesomet \"Low dose\" in fasted condition","slug":"tesomet-low-dose-in-fasted-condition","phase":"marketed","mechanism":"Tesomet is a combination of tesofensine (a monoamine reuptake inhibitor) and metformin that promotes weight loss by increasing satiety and energy expenditure while improving metabolic control.","indications":["Obesity or overweight with comorbidities (marketed in Europe)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNd2pReHBmRTZ0cXNnZjgwUVVYQVNrQUhMeU9JQ0kzR2FwMGZQOWJaU19KNkw4ODVsc3VQYkRnb2FQT2V4SkY2TElCQ1ZMSEFRa1MwMmhoR2NVY2Y0VnR4NEQzVVV5T2JYaUhBNUVLODAzUU4yeEp5U3l1RGtvRE5ab2VXNFB4dUxyUkg5dkFzclR4MW9RZFhaUzVGdTNqaDBLWDlCd1RBT3BkZkxxTXBIaTY1bkM2eEtJZkdleDBkdHFDS3VNYVE?oc=5","date":"2025-09-10","type":"deal","source":"The Healthcare Technology Report.","summary":"Jazz Pharmaceuticals Secures Global Rights to SAN2355 in Licensing Deal with Saniona - The Healthcare Technology Report.","headline":"Jazz Pharmaceuticals Secures Global Rights to SAN2355 in Licensing Deal with Saniona","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNbS12eHAxMlh6VWZVdnpOZ2ZmbDZRd3JOUktsWkEzV1dlUWQyLUpnU0taRHU1QkVVT180eGNuV0diaHpqaFB4MHAyT2JlLXpzYVB4MXBzVlptZ193MG1oMUtYa3dxWTlVUThoTDcyNmxQMDE3WUdidmRfLVR4NlhBVUdfNGZ4ZThyc2tPOXBUWWlhVHJmVG5xb0xNTFpGUmxINmxFS0kxckYwSUxkeXhva1B1N0szdEtYWVVIWXRDazlDcGluckJQMTRHbk9ZMFV4VUVNdE1zVHl1cUFxcndPLVBOOU51bTJBYk1vbFItM2FmUVRkQkE?oc=5","date":"2025-08-20","type":"pipeline","source":"PR Newswire","summary":"Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355 - PR Newswire","headline":"Jazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE1BQ0lGc2xzQjNNdlhwMHUtenVOUE1KeDBUU0hjQXhBVFlFMnJlZm1NQ1FjZkJsWUw2RkxfY1RMNUpHYlZvOFVpRlZBLXhxWnBTdTM0?oc=5","date":"2025-08-20","type":"deal","source":"FirstWord Pharma","summary":"Jazz inks $1B+ deal for Saniona's preclinical epilepsy candidate - FirstWord Pharma","headline":"Jazz inks $1B+ deal for Saniona's preclinical epilepsy candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxPS1RTRlVUVlNOUXNMakFkcThCeTRQYk9YdHZ5OGRiZVVJaWFDcEp3TTdGc0gyLVZzN0lhY29aOUFqZzhUSUs5SGFtTGRhaGJPS0RhYk9GTWN0RkVtejRxdnNFNFBjODhIZTlWTVptVnc0b2c0TFI4WTFzODA2VWJVd1YybGp6SkFhZDU4Q2NNTGtXckdnbkNaaHNCVUlERFFpYjBzeGRn?oc=5","date":"2025-08-20","type":"pipeline","source":"Fierce Biotech","summary":"Jazz pays Saniona $42.5M to add preclinical prospect to epilepsy ensemble - Fierce Biotech","headline":"Jazz pays Saniona $42.5M to add preclinical prospect to epilepsy ensemble","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPSTlaLWxWNXcxbVhIcV9hbE9XYkFzZHhTVXBNWVNaWlV5a3NlQVI4YXFXaWZLMTFxWHV5eHFJc0JWb3p4c3laTjE2SW5Zc2NSWUNRUnYxYkNDWEt0RndBMkhIanZITWhTQ1hlNl9TQUdZWW5xRlY3OTZDVEpobWY0bG5aYkJ0ekNucDhiUjMyY3puamREWm8yUERhdkpzY2Z3ZHc?oc=5","date":"2025-08-20","type":"pipeline","source":"Contract Pharma","summary":"Jazz Pharmaceuticals, Saniona Enter Exclusive Agreement - Contract Pharma","headline":"Jazz Pharmaceuticals, Saniona Enter Exclusive Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQUTNsRkR5NFpHdnI2b0dZSVE1WlN5WENhc0tUaHYtYlhFTGZHUXo5VmV5YVBnbzYzOUxGVmltMzJyN2FlUllJOFNNSUM0aW5sQzBlaFhHZllkR2NYR1NLaTBfcmg4VHhOUERyN1RpU0JIWnhsLXhzel9QcjF4WHczSGJMakJ1VmMtUHk1cVhwWS16TGRZbU1oNjY0MDJDejV2aFVYV2Zn?oc=5","date":"2025-08-20","type":"pipeline","source":"Pharmaceutical Executive","summary":"Jazz Pharmaceuticals & Saniona Enter an Exclusive Licensing Agreement to Develop and Commercialize SAN2355 - Pharmaceutical Executive","headline":"Jazz Pharmaceuticals & Saniona Enter an Exclusive Licensing Agreement to Develop and Commercialize SAN2355","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNa29CNmRBYzRXQ25KMlJVY0dBajgwQ2hQNGhGNDAzSnJYcldjRlBycGFUdm9YZkRVV004b3lXLTBoaFZaOVNVdlBuNUJjRk5OS0dVVHptSXJEYjlwMU40UnVrZU5sRndjRzhoNTZmZkR6MUhOR2pMeHhyWXBIMFZTWU1rVHd6OWlPRXdXYUdFdHNJTDFmMEtoOUgySVFVVTh0MTd2VkhWWE4wVDgtSUE?oc=5","date":"2025-08-20","type":"deal","source":"MedCity News","summary":"Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective Saniona Drug - MedCity News","headline":"Jazz Pharma Broadens Its Prospects in Epilepsy With Deal for Selective Saniona Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQMzloZktlc2dsaW9Za2ozWXdMVWdqUDRkbGpSYzVWeXl2ell6VGlrQi1sTUktcnZ4Y0FGOEVGblplQll0MFdUd053T1pWY1VXOWZ2el9HZ2dnb1huQ095WF8zemVRRzMwU3FMc2xxYkljSEFtQ05SR004amNvZUtlNllaUjlzSVBwMDI1NDQ2aWZqUkYxVGQ3S1lFWkE?oc=5","date":"2025-08-20","type":"trial","source":"Endpoints News","summary":"With $42M, Jazz turns to Copenhagen biotech to build out epilepsy pipeline - Endpoints News","headline":"With $42M, Jazz turns to Copenhagen biotech to build out epilepsy pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQMVROdi1PczNuYlp6YlJsQlIzV2Zyem5qTGppd2lDVjdVeE1YUk5SODZkSVRYRFM1X3dwTHRKOVJHVHEzLWhfX0ZxZ0N6OXJOdVZwcnBjRjd2dTZBT0I0cHA2SmFTVVhGTHhWaDJSVHVXWlBRczN6ajg3dGN5SjlobzJFY3RGaTJFbjMtTHl3QWZ2QQ?oc=5","date":"2025-06-04","type":"pipeline","source":"Biostock","summary":"Saniona's CFO on the strategy to reach clinical milestones - Biostock","headline":"Saniona's CFO on the strategy to reach clinical milestones","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxNTjhXYmtrT0FSTXg0WFBiTkxmX3pZZWE3YzVEcEQtb0thWVJCc1BLaVpsTGNmOXV1MDVpSnl3d1N4OWJOSWYtQU03Q2RXc216NFl2eC1CM0pZYXIwS1preWl4cDJzd1JZUkF6LTBfbGY0d05hU1VWaUF4bjJMMlZGNGhMdEs1eFU?oc=5","date":"2024-11-28","type":"deal","source":"The Pharma Letter","summary":"Acadia signs deal with Saniona for SAN711 rights - The Pharma Letter","headline":"Acadia signs deal with Saniona for SAN711 rights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPUVgxdDJ6NjMzTmhiRnVSWHc4ZXdaSENOLS1VU0FRTW5VQ200U1hxT0FudE5sTnBKUjJCM2ZRMXFqcTV1WG1kOUN5TWZPeTNhTGZkRnNjdVJweXI0cFVYX0F2bEI2V1VDUWxxNHhKUEM3RUMtZWtYT1BsdlZOaW9JQnNJRk1BQQ?oc=5","date":"2024-11-27","type":"pipeline","source":"Pharmaceutical Technology","summary":"Acadia signs agreement with Saniona to commercialise SAN711 - Pharmaceutical Technology","headline":"Acadia signs agreement with Saniona to commercialise SAN711","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQQlJoVWIzazN5ZTdmeW9pRVcyc2o1R1FpVHRMZlZUM2l1amliVGlKekVJS2dacHVnSmF6NnRITkpheU51VDJqTmRXMGcyV3BYMlphVWlXdTlyc08tY1pmZ2N6eVFXRWlWY3NqZ1BhemlBdktlbmY4TEZrckt6TWZ1MXJmelV1NmMxWWZ2dW1obDJXVm1VNWZCelVHUWlMdw?oc=5","date":"2024-11-26","type":"deal","source":"Fierce Biotech","summary":"Acadia nabs rights to Saniona's tremor asset in $582M biobucks deal - Fierce Biotech","headline":"Acadia nabs rights to Saniona's tremor asset in $582M biobucks deal","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"discontinued":1,"marketed":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}